Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Early inflammatory response in epithelial ovarian tumor cyst fluids.

Kristjánsdóttir B, Partheen K, Fung ET, Yip C, Levan K, Sundfeldt K.

Cancer Med. 2014 Oct;3(5):1302-12. doi: 10.1002/cam4.282. Epub 2014 Jun 20.

2.

Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.

Kristjansdottir B, Levan K, Partheen K, Sundfeldt K.

Gynecol Oncol. 2013 Oct;131(1):52-8. doi: 10.1016/j.ygyno.2013.07.094. Epub 2013 Jul 25.

3.

Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ.

Kristjansdottir B, Levan K, Partheen K, Carlsohn E, Sundfeldt K.

Clin Proteomics. 2013 Apr 4;10(1):4. doi: 10.1186/1559-0275-10-4.

4.

Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers.

Kristjansdottir B, Partheen K, Fung ET, Marcickiewicz J, Yip C, Brännström M, Sundfeldt K.

Clin Proteomics. 2012 Dec 27;9(1):14. doi: 10.1186/1559-0275-9-14.

5.

BAC CGH-array identified specific small-scale genomic imbalances in diploid DMBA-induced rat mammary tumors.

Samuelson E, Karlsson S, Partheen K, Nilsson S, Szpirer C, Behboudi A.

BMC Cancer. 2012 Aug 15;12:352. doi: 10.1186/1471-2407-12-352.

6.

Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass.

Partheen K, Kristjansdottir B, Sundfeldt K.

J Gynecol Oncol. 2011 Dec;22(4):244-52. doi: 10.3802/jgo.2011.22.4.244. Epub 2011 Dec 5.

7.

Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.

Osterberg L, Levan K, Partheen K, Delle U, Olsson B, Sundfeldt K, Horvath G.

Anticancer Res. 2010 Nov;30(11):4451-8.

PMID:
21115892
8.

Tumor cure probability during alpha-RIT of ovarian cancer with different radiation sensitivity.

Elgqvist J, Johansson BR, Partheen K, Danielsson A.

Anticancer Res. 2010 Jul;30(7):2545-51.

PMID:
20682981
9.

Identification of a gene expression signature for survival prediction in type I endometrial carcinoma.

Levan K, Partheen K, Osterberg L, Olsson B, Delle U, Eklind S, Horvath G.

Gene Expr. 2010;14(6):361-70.

PMID:
20635577
10.

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.

Osterberg L, Levan K, Partheen K, Delle U, Olsson B, Sundfeldt K, Horvath G.

BMC Cancer. 2009 Oct 18;9:368. doi: 10.1186/1471-2407-9-368.

11.

External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas.

Partheen K, Levan K, Osterberg L, Claesson I, Sundfeldt K, Horvath G.

BMC Cancer. 2009 Sep 23;9:336. doi: 10.1186/1471-2407-9-336.

12.

High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.

Osterberg L, Levan K, Partheen K, Staaf J, Sundfeldt K, Horvath G.

Cytogenet Genome Res. 2009;125(1):8-18. doi: 10.1159/000218744. Epub 2009 Jul 14.

PMID:
19617691
13.

Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas.

Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G.

Int J Cancer. 2008 Nov 1;123(9):2130-7. doi: 10.1002/ijc.23758.

14.

Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors.

Partheen K, Levan K, Osterberg L, Horvath G.

Eur J Cancer. 2006 Nov;42(16):2846-54. Epub 2006 Sep 22.

PMID:
16996261
15.

Chromosomal alterations in 98 endometrioid adenocarcinomas analyzed with comparative genomic hybridization.

Levan K, Partheen K, Osterberg L, Helou K, Horvath G.

Cytogenet Genome Res. 2006;115(1):16-22.

PMID:
16974079
16.

Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.

Osterberg L, Akeson M, Levan K, Partheen K, Zetterqvist BM, Brännström M, Horvath G.

Cancer Genet Cytogenet. 2006 Jun;167(2):103-8.

PMID:
16737908
17.

Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma.

Osterberg L, Levan K, Partheen K, Helou K, Horvath G.

Cancer Genet Cytogenet. 2005 Dec;163(2):144-50.

PMID:
16337857
18.

Supplemental Content

Loading ...
Support Center